Exelixis, Inc. (NASDAQ:EXEL) is set to announce third quarter earning results on Thursday 5th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, EXEL to report 3Q20 income of $ 0.01 per share.
For the full year, analysts anticipate top line of $ 922.00 million, while looking forward to income of $ 0.37 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 900.00 million ~ $ 950.00 million
Click Here For More Historical Outlooks Of Exelixis, Inc.
Previous Quarter Performance
Exelixis, Inc. came out with income for the second quarter of $ 0.25 per share, from the revenue of $ 259.48 million. According to street consensus, EXEL was expected to report 2Q20 income of $ 0.12 per share from revenue of $ 226.36 million. The bottom line results beat street analysts by $ 0.13 or 108.33 percent, at the same time, top line results outshined analysts by $ 33.12 million or 14.63 percent.
Stock Performance
Shares of Exelixis, Inc. traded up $ 1.50 or 7.11 percent on Wednesday, reaching $ 22.59 with volume of 2.02 million shares. Exelixis, Inc. has traded high as $ 23.10 and has cracked $ 21.54 on the downward trend
The closing price of $ 22.59, representing a 54.28 % increase from the 52 week low of $ 13.67 and a 24.14 % decrease over the 52 week high of $ 27.80.
The company has a market capital of $ 6.98 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 22nd September 2020, maintained by Morgan Stanley at Equal-Weight rating, with $ 29.00 target price.
- On 21st September 2020, maintained by Piper Sandler at Overweight rating, with $ 33.00 target price.
- On 21st September 2020, maintained by Oppenheimer at Outperform rating, with $ 37.00 target price.
Conference Call
Exelixis, Inc. will be hosting a conference call at 5:00 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.exelixis.com
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The companys products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.
